Welcome to our dedicated page for Renovaro SEC filings (Ticker: RENB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lunai Bioworks Inc. filings document the public-company record for an AI-powered drug discovery and biodefense issuer with Nasdaq-listed common stock and operating assets tied to biomedical AI, BioSymetrics, and patent rights.
Recent disclosures include Current Reports on Form 8-K covering material agreements, completion of a triangular merger involving Lunai Bioworks IP, Inc. and a multi-jurisdictional patent portfolio, and special-meeting matters. Proxy materials describe stockholder votes on reverse stock split authority, adjournment mechanics, quorum and voting procedures, and related capital-structure governance. Other filing categories address material events, operating and financial results, clinical or regulatory disclosures, security registration, and changes affecting the company's name, trading symbol, and common-stock structure.
Lunai Bioworks, Inc. reported that the Court of Amsterdam declared its indirect subsidiary Gedi Cube B.V. bankrupt on September 2, 2025, following Gedi’s voluntary petition after it could no longer meet its payment obligations. A court-appointed receiver will oversee the bankruptcy process. Lunai is evaluating how this development may affect its supply chain, customer relationships, and projects that had relied on Gedi, and management is putting contingency plans in place to limit operational disruption.
In connection with this bankruptcy, Lunai’s management concluded that a material impairment of assets has occurred and expects to record an impairment charge in the quarter ending September 30, 2025. The company plans to disclose the impairment in its upcoming Form 10-Q or earlier if available. Lunai emphasized that neither the parent company nor any other subsidiaries are seeking bankruptcy protection and that their operations will continue as usual.
Renovaro Inc. reported that it has amended its Restated Certificate of Incorporation to change its corporate name to Lunai Bioworks Inc. The amendment was filed in Delaware on August 18, 2025, and the name change became effective on August 20, 2025.
The company’s common stock will continue to trade on Nasdaq under the ticker symbol RENB, although the CUSIP number for the common stock will change as a result of the new name. The company also includes forward-looking statements about plans to hold its annual meeting and regain compliance with Nasdaq listing standards.
Renovaro Inc. (Nasdaq: RENB) disclosed in an 8-K that it received a Nasdaq Listing Rule 5620(a) deficiency notice on 7 July 2025 for failing to hold its FY 2024 annual shareholder meeting within 12 months of the 30 June 2024 fiscal year-end.
The company has 45 calendar days to submit a remediation plan; if Nasdaq accepts it, Renovaro could receive an extension until 29 December 2025 to regain compliance. Until then, the stock will continue trading on Nasdaq. Failure to file an acceptable plan or to hold the meeting by the deadline could lead to delisting.
Management states it is “working diligently” to prepare the plan and schedule the meeting “as soon as practicable.” No other operational or financial metrics were disclosed.